The antitumor effects of an arsthinol–cyclodextrin complex in a heterotopic mouse model of glioma
Selma Becherirat, Marie-Claire Lanthers, Marie Socha, Mehdi Yemloul, Alain Astier, Caroline Loboda, Nathalia Aniceto, Stéphane Gibaud

To cite this version:
Selma Becherirat, Marie-Claire Lanthers, Marie Socha, Mehdi Yemloul, Alain Astier, et al.. The antitumor effects of an arsthinol–cyclodextrin complex in a heterotopic mouse model of glioma. European Journal of Pharmaceutics and Biopharmaceutics, Elsevier, 2013, 83 (3 Pt A), pp.560-568. 10.1016/j.ejpb.2013.06.021 . hal-01169157

HAL Id: hal-01169157
https://hal.archives-ouvertes.fr/hal-01169157
Submitted on 5 Jul 2015

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
The antitumor effects of an arsthinol-cyclodextrin complex in an heterotopic mouse model of glioma

Selma Becherirat\textsuperscript{a}, Marie-Claire Lanhere\textsuperscript{b}, Marie Socha\textsuperscript{a}, Mehdi Yemloul\textsuperscript{c}, Alain Astier\textsuperscript{d}, Caroline Loboda\textsuperscript{a}, Nathalia Aniceto\textsuperscript{a} and Stéphane Gibaud\textsuperscript{a*}

\textsuperscript{a} : EA 3452 – CITHEFOR – Université de Lorraine -  5, rue Albert Lebrun (Faculté de pharmacie) – 54000 Nancy - France

\textsuperscript{b} : EA 4421 – SIGRETO – Université de Lorraine - 9, avenue de la forêt de Haye (Faculté de médecine) – 54500 Vandœuvre-lès-Nancy - France

\textsuperscript{c} : Méthodologie RMN (CRM2, UMR 7036 CNRS-Nancy-Université), Faculté des Sciences et Technologies, BP 70239, 54506 Vandœuvre-lès-Nancy Cedex, France

\textsuperscript{d} : Pharmacy –Toxicology Department, CHU Henri Mondor, 51 avenue du Maréchal de Lattre, 94010, Créteil, France

Corresponding author. Tel.: +33 3 83 68 23 10; fax: +33 3 83 68 23 01. E-mail address: stephane.gibaud@univ-lorraine.fr
Abstract

In this paper, we examined arsthinol-cyclodextrin complexes, which display an anticancer activity. The association constants were $17.502 \pm 522 \text{ M}^{-1}$ for hydroxypropyl-$\beta$-cyclodextrin and $12.038 \pm 10.168 \text{ M}^{-1}$ for randomized methylated $\beta$-cyclodextrin. $^1$H-NMR experiments in solution also confirmed the formation of these complexes and demonstrated an insertion of the arsthinol (STB) with its dithiarsolane extremity into the wide rim of the hydroxypropyl-$\beta$-cyclodextrin cavity. Complexed arsthinol was more effective than arsenic trioxide ($\text{As}_2\text{O}_3$) and melarsoprol on the U87 MG cell line. Importantly, in the *in vivo* study, we observed significant antitumor activity against heterotopic xenografts, after i.p. administration and did not see any signs of toxicity. This remains to be verified using an orthotopic model.

**Keywords:** glioma; glioblastoma; arsenic; cancer; brain tumors
1. Introduction

Although brain tumors are relatively rare, they represent approximately 2% of all cancer diseases and constitute an important cause of morbidity and mortality. The age-adjusted SEER\(^1\) (Surveillance Epidemiology and End Results from the National Cancer Institute) incidence of brain tumors is approximately 6.6/100 000 in the United States [1]. Gliomas comprise approximately 33% of all brain tumors and 79% of malignant brain tumors [2]. It is a group of heterogeneous neoplasms that differ in location within the central nervous system, age and sex distribution, growth potential, invasiveness, morphological features, tendency for progression and response to treatments. The most common malignant glioma is the glioblastoma, which is associated with a median survival of 12–15 months.

Temozolomide is an oral drug that is rapidly metabolized into methyltriazeno-imidazole-carboxamide (MTIC\(^2\)), a DNA-methylating drug. A DNA repair enzyme, methyl-guanine methyltransferase (MGMT\(^3\)), can remove the methyl group and overcome the modification of cells that lack MGMT, which have been shown to have a higher sensitivity to temozolomide. The EORTC\(^4\) (European Organization for Research and Treatment of Cancer) has published a study on the concomitant use of radiation therapy and adjuvant temozolomide, which slightly improved mortality (9.8% after 5 years). This treatment is now adopted as the new standard treatment.

In addition to temozolomide, other compounds (bevacizumab, VEGF receptor tyrosine kinase inhibitors [pazopanib, lapatinib, erlotinib], procarbazine, lomustine and vincristine) have been tested in clinical trials, but only the phase II studies have

---

\(^1\) SEER: Surveillance Epidemiology and End Results from the National Cancer Institute
\(^2\) MTIC: methyltriazeno-imidazole-carboxamide
\(^3\) MGMT: methyl-guanine methyltransferase
\(^4\) EORTC: European Organization for Research and Treatment of Cancer
been published. Low molecular weight kinase inhibitors may have advantages in terms of drug delivery, whereas monoclonal antibodies have greater specificity but face delivery restrictions. To date, few molecularly targeted therapies have demonstrated significant antineoplastic activity, possibly due to tumor heterogeneity. Arsenic trioxide (As$_2$O$_3$) has also been shown to be effective in glioma cells and in mice models. This compound can induce autophagy and apoptosis [3], and it inhibits at relatively low concentrations in U87 and T98G cells in vitro [4]. This finding was confirmed with orthotopic malignant gliomas growing in the brains of mice but only in combination with radiotherapy [5].

In this paper, we focus on an organoarsenical drug (i.e., Arsthinol, STB$^5$, Fig.1), which displays an anticancer activity. This drug was marketed in 1953 as amoebicide tablets [6, 7], and it has recently demonstrated a strong anticancer activity after intravenous (i.v.) injections [8-13].

From a chemical perspective, STB belongs to the dithiarsolane series, which includes melarsoprol (MEL B$^6$) as the lead compound. This latter drug is used as a trypanocide in Africa, and its formulation in propylene glycol can lead to adverse side effects, often causing severe pain for patients during i.v. injection. Because these drugs are very poorly soluble in water, we also suspect their precipitation in plasma as soon as the drug enters the vein and is diluted in the blood, which can lead to thrombosis in some cases.

The i.v. use of the drug has also been limited because of its cerebral toxicity. After injection, the rapid increase in concentration can lead to arsenical encephalopathy.

---

$^5$ STB : arsthinol  
$^6$ MEL B : melarsoprol
A few years ago, we proposed cyclodextrin (CD\(^7\)) complexes (hydroxypropyl-\(\beta\)-cyclodextrin/melarsoprol and methyl-\(\beta\)-cyclodextrin/melarsoprol) that could allow for oral absorption [14]. These complexes were characterized by an improved absorption and reduced peak/valley ratio. As expected, the tolerance for this formulation was better, and surprisingly, the therapeutic effect was also significantly improved, with no CNS toxicity observed at therapeutic dose [15].

We attempted to apply this concept to STB/cyclodextrin complexes. This dithiarsolane was chosen because it has the best anticancer activity of this series of compounds, to our knowledge [11, 13, 16].

2. Materials and methods

2.1. Materials

STB and melarsoprol were synthesized according to the method described by Friedheim [9, 17, 18]. Its chemical structure is presented in Fig. 1. The organoarsonic purity was greater than 99%, confirmed by the HPLC analysis, and its structure was ascertained by \(^1\)H- and \(^{13}\)C-NMR.

The cyclodextrins [randomly methylated-\(\beta\)-cyclodextrin (1.6–2.0 methyl unit per anhydroglucose unit; RAME\(\beta\)CD) and hydroxypropyl-\(\beta\)-cyclodextrin (HP\(\beta\)CD)] were purchased from Sigma–Aldrich (St. Quentin, France). In all experiments, the water content of the CDs was determined by the coulometric Karl–Fisher method and then the weighed mass of the CDs was adjusted accordingly. All other reagents were of analytical grade from either VWR (Fontenay-sous-Bois, France) or Sigma–Aldrich (St. Quentin, France) and were used as received. RPMI 1640 with Glutamax-I and

\(^7\) CD : cyclodextrin
antibiotic/antimycotic were purchased from Gibco (Gibco Invitrogen, Cergy Pontoise, France).

2.2. Characterization of STB*CD complexes

2.2.1. HPLC assay for STB quantification

STB samples were analyzed using a reverse-phase high performance liquid chromatography (HPLC). Twenty microliters of each sample were injected, using a Spectra Physics® AS1000 injector, onto a C18 column (Nucleosil® 100-5 C18 AB, 5µm, 240 x 4 mm, Macherey-Nagel, Eckbolsheim, France). The samples were eluted at a flow rate of 1.0 mL/min (Spectra Physics P1000XR, Thermo Electron S.A., France) with a mobile phase consisting of acetonitrile and acetic acid 0.6% (45:55, v/v). The elution took place at room temperature under isocratic conditions. In these analytical conditions, the limit of detection was 0.12 µM and the limit of quantification was 0.39 µM. Standard solutions (1.5 µM to 20 µM) used to build the standard curve (CV < 3.5%) were prepared by dissolving the appropriate amount of powdered drug in methanol and bringing the solution up to the final volume with phosphate buffer (0.1 M, pH 7.4).

2.2.2. Phase solubility studies of STB complexation

STB complexation with various cyclodextrins was evaluated using the phase-solubility method [19]. A suspension of a large excess of STB in 2 mL of aqueous solutions of the appropriate CD (concentrations ranging from 9.5 to 191 mM in 0.1 M phosphate buffer pH 7.4) was stirred in screw-capped amber vials for 18 h on a rock-and-roller agitator at 25°C. Under these conditions, the solution primarily contained
the non-ionized STB (pKa 9.5, [20]), and no significant degradation of the drug was observed. Preliminary time-dependence experiments showed that the equilibrium was reached after this period of stirring. Each suspension was then centrifuged at 7200 × g for 5 min and diluted 1:100 with 0.1 M phosphate buffer pH 7.4; the amount of dissolved STB was then quantified by HPLC as described above.

The apparent solubility of the substrate ([STB]ₐ) was determined as a function of the added ligand concentration ([CD]ₐ). Because the phase solubility diagrams were of A₁-type and a 1:1 complex was assumed, the apparent stability (or formation) constant $K_c$ was calculated for each CD using the slope from the linear regression analysis of the phase-solubility isotherm using the following equation:

$$K_c = \frac{\text{slope}}{S_0(1-\text{slope})} \quad \text{Eq. (1)}$$

The inherent solubility of STB ($S_0$) was determined in pure water under identical conditions. The determinations were performed in triplicate, and the constants were expressed as the mean ± S.D.

2.2.3. Determination of the apparent complexation constant by potentiometric titration

For the potentiometric titration procedure, a set of solutions with increasing concentrations of CD ($2.5 \times 10^{-5}$ to $6 \times 10^{-5}$ M) and a constant drug content ($1 \times 10^{-5}$ M) were prepared, with a final volume of 16 mL.

To maintain the ionic strength, phosphate buffer (0.1 M, pH 7.4) was used. A control STB solution was also prepared in the phosphate buffer medium without CD to
calculate the reference $K_a$ value. After one hour of incubation at room temperature to allow for complexation, the solutions were acidified to pH 4 with 0.05 M HCl and then 0.05 M KOH was added progressively up to pH 11 to form the titration curve. After each KOH addition, the pH was recorded. The pH and titrant volumes were used to calculate the $K_a$ value through the second derivative method [21].

The apparent complexation constant was calculated as previously described by Kahle and colleagues [22].

### 2.2.4. Determination of the complex structure by $^1$H-NMR measurements

Because the results that we obtained were similar for both cyclodextrins, we chose to focus on HPβCD for the remainder of the study. Additionally, this cyclodextrin was already complexed with melarsoprol and this drug has now an "orphan drug designation" from the European Medicine Agency (i.e., trypanocidal activity of the melarsoprol/HPβCD complex [15]). The results from $^1$H NMR, $^{13}$C NMR, ROESY, NOESY, HSQC, and 2D-HSQC-NOESY analyses of HPβCD and the complex (STB*HPβCD) were obtained at 298 K in D$_2$O on a Bruker Avance III 600 MHZ using a 5 mm broad band direct probe. Spectral widths of 6000 Hz and 30000 Hz were used for $^1$H NMR and $^{13}$C NMR, respectively. 2D NMR spectra were acquired by pulse field gradient-selected methods. 2D ROESY spectrum was acquired with a 2048 time domain in F2 and 256 experiments in F1, using the TPPI method and a mixing (spin-lock) time of 300 ms at a field of approximately 4 kHz.

The 2D HSQC-NOESY spectra were recorded with a 4096 time domain in F2 and 256 experiments in F1 using the Echo-Antiecho method and a mixing time of 500 ms.
2.3. Cell cultures - *in vitro* activity on U87MG cells

U87 MG glioma cells were cultured in monolayers (37°C, 5% CO$_2$) in DMEM supplemented with fetal calf serum (10%), an antibiotic mixture of penicillin and streptomycin (1%) and glutamine (1%). Coarse STB and MEL were dissolved in DMSO leading to final concentrations of DMSO < 1% (blank controls of DMSO did not show any toxicity); STB*HPβCD was spontaneously dissolved in the culture medium.

The classical MTT test was used to determine growth inhibition and cytotoxic activity after treatment with STB, STB*HPβCD, As$_2$O$_3$ or melarsoprol. Exponentially growing cells were seeded into 96-well plates (4 x 10$^4$ cells/mL) and incubated with each compound at different concentrations (0.01 µM to 1 mM, 24 h or 48 h, 37°C, 5% CO$_2$). Cell viability was directly proportional to the production of formazan (λ = 570 nm).

2.4. Animal studies

Pathogen-free, 6-8 week-old female athymic NMRI-nu (nu/nu) mice were purchased from Charles River (Saint Germain sur l'Arbresle, France).

Animal handling procedures were performed in accordance with national animal care guidelines (European Commission directive 86/609/CEE; French decree no. 87-848). Animals were housed in solid-bottomed plastic cages with free access to tap water and food ad libitum. Rearing conditions were a room temperature of 23 ± 1°C, a relative humidity of 60%, and a 12h/12h light/dark cycle.
2.4.1. Maximum Tolerated Dose (MTD)

Maximum Tolerated Doses (MTD) were determined to set the doses of animal experiments. Groups of 5 animals have received various doses of STB*RAMEβCD and As$_2$O$_3$ (i.p. and oral) 5 days/week. The first dose was set from our experience of these compounds [9] (0.15 mmol/kg for STB*RAMEβCD and 0.06 mmol/kg for As$_2$O$_3$) and was increased by steps of 0.01 mmol/kg. The highest dose that results in no lethality, <15% weight loss and no other sign of toxicity was recorded as MTD.

2.4.2. Glioma mouse model

U87 MG is a commonly studied grade IV glioma cell line (anaplastic astrocytoma, ATCC HTB-14) that has been studied for more than four decades. These cells were cultured in monolayers as described above. Heterotopic tumor grafts were achieved as followed: a subcutaneous injection of $10^6$ U87 MG cells (in 5% glucose) was performed into each hind leg of mice. Tumors obtained from these source mice were used for the production of heterotopic transplants, by subcutaneous implantation (inguinal area) of a fragment of approximately 2 mm$^3$ in new mice, under anesthesia. Three successive subcutaneous relocations were performed in other mice, when tumors reached approximately 1000 mm$^3$, before using for our experiment (subcutaneous implantation of a 2 mm$^3$ fragment in experimental mice). The size of the tumor was assessed with a vernier caliper (large diameter = D and small diameter = d) to obtain the volume $V = D \times d^2/2$. 
Treatments started when the volume of the tumor exceeded $280 \pm 50 \text{ mm}^3$, and the solutions [STB*RAMEBCD (i.p. and oral), arsenic trioxide (i.p. and oral)] were administered 5 days/week. Each group (treated and control) was composed of 9 mice.

Since the route of administration were i.p. and oral, the bioavailability is always below 100% and this may impact the efficacy of the treatment, we chose to compare each group at 65% of the MTD (see section 3.5).

The size of the tumor was measured with a vernier caliper 3 times a week. Experiments were stopped when the size reached $2000 \text{ mm}^3$ (survival endpoint).

Other ethical parameters inconsistent with the continued life of animals, such as a weight loss of greater than 15% of initial weight, major disturbances in physiological and/or neurological functions, were also taken into account as endpoints.

The Mann-Whitney $U$ test was used to evaluate the statistical significance of the results. Kaplan-Meier curve analysis was performed for survival analysis, using the log-rank test (GraphPad Prism version 5.00 for Mac Os X, GraphPad Software, San Diego California USA).

2.4.3. Arsenic concentration in the organs after oral and i.p. administration

Brains, tumors, kidney, spleens, intestines and livers were removed from all the animals when the survival endpoint was reached (2 h 30 min after the last administration). The organs were weighed and stored at $-20^\circ\text{C}$ until analysis.

The amount of total arsenic in the samples was determined using a colorimetric method [23] after digestion with nitric acid ($\text{HNO}_3$; 65%) and hydrogen peroxide
(H$_2$O$_2$; 30%). In brief, each sample (tissues or plasma) was placed in a digestion tube with 5 mL HNO$_3$ (65%) and 5 mL H$_2$O$_2$ (30%). The tubes were heated with a digester apparatus DK-20 (Velp Scientifica, Milan, Italy) by slowly increasing the temperature from 100°C to 200°C. The clear solution was evaporated to dryness, and the residue was solubilized with 10 mL of HCl (2 M) and introduced into an arsine generator apparatus (European Pharmacopoeia). The reaction was initiated by zinc powder after reduction to trivalent arsenic (As$^{III}$) with tin chloride (SnCl$_2$; 40%) and potassium iodide (KI; 15%). After 30 min, the pentavalent arsenic (As$^V$) was completely reduced to arsine (AsH$_3$), and the gas bubbled through a solution of the silver salt of diethyldithiocarbamate in pyridine. The absorbance of the brown complex was measured at 525 nm (Cary-50 spectrophotometer, Varian, Palo Alto, USA). A calibration curve was obtained with increasing amounts of arsenic (As$_2$O$_3$, 0–0.09 mmol, $n = 3$, CV< 4.2%).
3. Results and discussion

3.1. Characterization of STB*CD complexes

3.1.1. Phase solubility studies of STB complexation

Our main objective was to develop a complex of STB with cyclodextrins (STB*RAMEßCD and STB*HPßCD). To our knowledge, this STB compound was the best anticancer dithiarsolane [9, 13]; it is a lipophilic compound (log P = 2.34), and its solubility is very poor, though slightly better than that of melarsoprol.

The classical phase solubility study, first described by T. Higuchi and K.A. Connors [19], demonstrates the potent solubility properties of cyclodextrins. RAMEßCD and HPßCD showed a very good solubilization effect on STB (Fig. 2). Both cyclodextrins isotherms were linear within the CD concentration range studied, corresponding to A_v-type profile with a slope less than 1 and indicating that the inclusion complexes could be of the first order with respect to the CDs (1:1 stoichiometry).

In this case, the method can be used for the determination of K_c using the slope of the curve. However, the standard deviation was very large (24 058 ± 20 738 M⁻¹ for HPßCD and 18 697 ± 7426 M⁻¹ for RAMEßCD). Therefore, these results should be confirmed by another method.
3.1.2. Determination of the apparent complexation constant by potentiometric titration

Potentiometric titration offers several advantages in terms of simplicity and accuracy over many methods [27-31].

The dissociation equilibria in STB*CD solutions correspond to Eq. (2) and Eq.(3)

\[
K_{a}^{\text{STB}} = \frac{[H^{+}][\text{STB}^{-}]}{[\text{STB}]} \quad \text{Eq. (2)}
\]

\[
K_{a}^{\text{STB*CD}} = \frac{[H^{+}][\text{STB}^{-} \text{CD}]}{[\text{STB} \text{CD}]} \quad \text{Eq. (3)}
\]

\(K_{a}^{'}\) corresponds to the apparent \(K_{a}\) of STB/CD mixtures and depends on the concentration of each species.

Thus, for the 1:1 complex, the CDs may form an inclusion complex with both STB and STB\(^{-}\). According to Connors and Lipari [32], Eq.(2) and Eq.(3) lead to the following equation in which:

\[
\frac{K_{a}^{'}\text{STB}}{K_{a}^{\text{STB}}} = 1 + \frac{(K_{c}^{\text{STB}} - K_{c}^{\text{STB}}^{*})[\text{CD}]}{1 + K_{c}^{\text{STB}}} \quad \text{Eq. (4)}
\]

This equation can be expressed in a double reciprocal (Benesi-Hildebrand or Lineweaver-Burk) form as follows:

\[
\frac{K_{a}^{'}\text{STB}}{K_{a}^{\text{STB}}} = \frac{1}{(K_{c}^{\text{STB}} - K_{c}^{\text{STB}}^{*})[\text{CD}]} + \frac{K_{c}^{\text{STB}}}{(K_{c}^{\text{STB}} - K_{c}^{\text{STB}})} \quad \text{Eq. (5)}
\]
This formula can be used for plotting the experimental data (pK' or K' values) in a linearized form where [CD] is the free cyclodextrin concentration (=[CD] - [STB]), [CD] is the total cyclodextrin concentration and [STB] the total STB concentration. By plotting $K_{c}^{STB}/(K_{c}^{'} - K_{c}^{STB})$ as a function of $1/([CD] - [STB])$, $K_{c}^{STB}$ and $K_{c}^{STB'}$ are obtained as follows (Fig. 3):

$$K_{c}^{STB} = \frac{\text{ordinate intercept}}{\text{slope}}$$  \hspace{1cm} \text{Eq. (6)}

$$K_{c}^{STB'} = \frac{1+\text{ordinate intercept}}{\text{slope}}$$  \hspace{1cm} \text{Eq. (7)}

The first titration curve (i.e., without CD) displays the pK_a of STB (9.61 ± 0.12 [Fig. 3]) and was consistent with the value published by Hiskey in 1968 [20].

The determination of the complexation constant gave $K_{c}^{STB} = 17502 ± 522 \text{ M}^{-1}$ and $K_{c}^{STB'} = 20835 ± 67 \text{ M}^{-1}$ for HPβCD, and $K_{c}^{STB} = 12038 ± 10168 \text{ M}^{-1}$ and $K_{c}^{STB'} = 37038 ± 13113 \text{ M}^{-1}$ for RAMEβCD.

These values were consistent with those of the dissolution study. We therefore considered this complexation to have a very strong association.

\subsection*{3.1.3. Determination of the complex structure by $^1H$-NMR measurements}

A 2D-ROESY experiment was used to characterize the inclusion complex of STB and 2-hydroxypropyl-β-cyclodextrin. This technique is widely used and enables the
identification of host-guest intermolecular interactions [33]. In our case, the overlapping of the STB peaks (b, c, d, g, Table 1) with those of cyclodextrin (between 3.5 and 4 ppm) and the variation of chemical shifts when passing from pure solution to complex and when changing the solvent made the identification of intermolecular cross peaks with the aromatic portion ambiguous (Fig. 4a).

To avoid this problem and clearly identify the complex, we used the large spectral dispersion of $^{13}$C through the 2D-HSQC/NOESY sequence, which provides a conventional 2D HSQC spectrum correlating the chemical shifts of $^{13}$C in the F1 dimension (vertical) and protons in the F2 dimension (horizontal), in which there are two types of cross peaks for each $^{13}$C resonance: the direct coupling $^1\text{J}(\text{CH})$ and the NOE $^1\text{H} - ^{13}\text{C}$ due to the cumulative transfer of $^1\text{J}(\text{CH}) + ^1\text{H} - ^1\text{H}$ NOE.

The intensities of the NOESY correlation peaks allowed us to characterize, in relative terms, the interatomic distances. From these intensities (green circles, Fig. 4b), we can say that the proton (e') is the nearest proton of 5 and 6, followed by the proton (e) and finally the proton (f) (whose correlation can result from relayed interactions, not from direct spatial proximity).

This study suggests that the aromatic ring is deeply inserted into the cavity following the scheme proposed in Fig. 5.

### 3.2. In vitro activity

The results have confirmed that this organoarsenical drug, such as arsenic trioxide [3], has a potential for the treatment of glioma.
Because STB was more cytotoxic than \( \text{As}_2\text{O}_3 \), the toxicity/activity ratio (therapeutic index \( \text{T.I.} = \frac{\text{LD}_{50}}{\text{IC}_{50}} \)) was used for a better comparison among the three compounds. The LD\(_{50}\) values were previously published [9], and the IC\(_{50}\) values were taken from the 48 h time point (Fig 6). The T.I. ratio, which was 16.8 for \( \text{As}_2\text{O}_3 \) and 12.6 for melarsoprol, was significantly improved for STB (T.I. = 143).

Until this study, dithiarsolanes (i.e., melarsoprol or STB) had not been tested for the treatment of glioma, and the only proven use of these compounds for treating cancer had been described for leukemias [24]. During the last decade, the anticancer properties of trivalent arsenical derivatives have been partially elucidated. Their strong activity has been attributed to the linkage between the arsenical compounds and the thiol moieties present on numerous proteins.

\( \text{As}_2\text{O}_3 \) is the main arsenical compound that has been studied and tested on a series of glioma cells (U373, U87, U251, GBM, A-172 and T98G) [25]. The IC\(_{50}\) of \( \text{As}_2\text{O}_3 \) (< 2 \( \mu\text{M} \)) was considered as clinically safe. This compound induces autophagy at low concentrations but induces apoptosis at higher concentrations (approximately 8 – 16 \( \mu\text{M} \)). BNIP3 (Bcl-2/adenovirus E1B 19-kDa-interacting protein 3) is upregulated in \( \text{As}_2\text{O}_3 \)-induced autophagic cells and seems to play a central role in arsenic-induced autophagic cell death in malignant glioma cells [26].

Since STB*HPβCD is administered orally and necessarily dissociated during digestion, the IC\(_{50}\) of STB is relevant to discuss the efficacy of this compound. Nevertheless, we have shown that the cytotoxicity of this complex is 31.6 ± 9.7 \( \mu\text{M} \).
3.3. *In vivo* experiments

The MTD are detailed in table 2. These results confirm that STB*RAMEβCD has a lower toxicity than As$_2$O$_3$ and are in good agreement with the results previously obtained for STB LD$_{50}$ [9].

In subsequent experiments, we chose doses of 65% of the MTD for administration of i.p. STB*RAMEβCD, i.p. As$_2$O$_3$ and oral As$_2$O$_3$. For oral STB*RAMEβCD, the MTD was too high, and for technical reasons, it was not possible to give more than 3 mmol/kg; consequently, this dose was arbitrarily fixed at 10 $\times$ the i.p. dose (Table 2).

During the treatment of the tumor-bearing mice, the animals were inspected daily for signs of pain, distress or morbidity.

The evaluation of overall clinical condition included general appearance and behaviour (dehydration, wasting away, hypothermia, laboured respiration, wound, ruffled fur, abnormal vocalization, abnormal posture, lethargy, impaired behaviour as hyper- or hypoactivity, ataxia, circling, tremors, convulsions). For the i.p. treatments, we were vigilant about ulcerations or inflammations near the injection area.

For each curve, a progressive growth (Fig. 7) of the average tumor volume has been observed in the first days until the first animal until the first animal died.

Compared with the control group, the average tumor volume increases more slowly after i.p. administration of As$_2$O$_3$ or STB*HPβCD (Fig. 7a).

The Kaplan-Maier survival curves are shown in Fig.8a, and the differences between these two groups (i.e., As$_2$O$_3$ i.p. and STB*HPβCD i.p.) are significant ($p = 0.049$, log-rank [Mantel Cox] test). The median survival after As$_2$O$_3$ i.p. treatment was 15 days a very near that of the control group (14 days), whereas survival after
STB*HPβCD i.p. treatment reached 21 days (Fig. 9) and was statistically different from that of the other groups (p<0.05).

The effects observed *per os* were not statistically different from those of the control group (Fig 7b, 8b). The median survival of the controls was 13 days. It reached 14 days with As$_2$O$_3$ *per os* and 17 days with STB*HPβCD *per os*.

Arsenic amount was analyzed in different organs of few mice treated with STB/HPβCD during 28 days (the maximum duration for *per os* treatment). It was detected in liver and brain for the i.p. group, and in liver, spleen, kidney, small intestine and brain for the *per os* group.

For this last group, low concentrations of arsenic were found in the liver and spleen (Table 3). Higher concentrations were found in the intestine (202 nmol/g), most likely due to the route of administration.

The arsenic concentrations in the heterotopic tumors were 21 nmol/g and 14 nmol/g after i.p. and oral administration, respectively. These values has to be compared with the IC$_{50}$ (2.8 ±0.7 µM after 48 h) and the IC$_{90}$ (29.9 ± 8.7 µM after 48 h) which are very near these tissue concentrations (Fig. 6).

Not surprisingly, the brain, which contains important amounts of membrane lipids, has high concentrations of the drug (693 nmol/g and 217 nmol/g after i.p. and oral administration, respectively). This finding confirms other i.v. studies performed with melarsoprol and STB [34].

The concentrations of arsenic in the heterotopic tumors were not very high (21 nmol/g and 14 nmol/g after i.p. and oral administration, respectively), although the efficacy was good. This study was performed on heterotopic tumors, which were
chosen as a first step for their simplicity. However, an orthotopic tumor would likely be impacted by the high concentrations of drug in the brain tissue.
4. Conclusion

This paper demonstrates that the very poorly soluble drug STB forms a 1:1 inclusion complex with both cyclodextrins (HPβCD and RAMEβCD).

The association constants determined by the solubility method and by potentiometry are high and in good agreement for both methods. The values are also closely related for both CDs (HPβCD and RAMEβCD), suggesting a similar inclusion process.

$^1$H-NMR experiments in solution also confirmed the formation of the complexes and demonstrated an insertion of the STB with its dithiarsolane extremity into the wide rim of the CD cavity.

Complexed STB (STB*HPβCD) was more effective than arsenic trioxide ($\text{As}_2\text{O}_3$) and melarsoprol on the U87MG cell line. Importantly, the $\textit{in vivo}$ study did not show any signs of toxicity, and we observed a significant antitumor activity after i.p. administration.

Consequently, we consider that this treatment is promising, and we believe that the oral route is suitable for this type of drug. The oral complexed melarsoprol that we have studied in previous studies, which is quite similar, gave very good results in a CNS-trypanosomiasis mouse model (i.e., no signs of toxicity and a resolution of CNS-stage infections).
References


Fig. 1: The chemical structure of STB.

Fig. 2. Phase solubility diagrams of STB in the presence of RAMEβCD (■) or HPβCD (-○-) in distilled water at 25°C. Mean ± S.D.

Fig. 3. Plot of STB with RAMEβCD (■) and with HPβCD (-○-). Mean ± S.D.

Fig 4a: ROESY spectrum of the complex (STB*HPβCD) obtained with a mixing time of 500 ms. The cross peaks, surrounded by red circles, cannot clearly be attributed to intermolecular dipolar interactions [i.e., interaction of HPβCD protons with those of the aromatic moiety of STB].
Fig 4b: 2D HSQC-NOESY spectrum of the complex. Red dots indicate the HSQC peaks of the HPβCD, correlated with HSQC peaks of STB (e, e’, f, red circles) via NOESY interaction (green circles).

Fig. 5. Molecular model of STB*HPβCD derived from the 2D HSQC-NOESY spectrum.

Fig. 6. Cytotoxicity parameters of STB, STB*HPβCD, As₂O₃ and melarsoprol on U87 cells. a) IC₅₀. b) IC₉₀. Mean ± S.D.

Fig. 7: Tumor growth after STB*HPβCD administration (-▲-) As₂O₃ administration (-■-) and in control mice (-●-). Starting value: 100% correspond to approximately 200 mm³. a) Intraperitoneal administration (65% of the MTD). b) Oral administration (As₂O₃ - 65% of the MTD; STB*HPβCD - 10 x MTD i.p.). n = 9 mice – Mean ± SD. * p< 0.05 vs control, Mann-Whitney.

Fig. 8: Percent of mice bearing tumors < 2000 mm³ in the three treatment regimens. a) After intraperitoneal administration (65% of the MTD). b) After oral administration (As₂O₃ - 65% of the MTD; STB*HPβCD - 10 x MTD i.p.). n = 9 mice.

Fig. 9: Survival days of each group (Control, As₂O₃ and STB*HPβCD) after i.p. and oral treatment. Mean ± S.D., n=9; * : p<0.05, Mann-Whitney

Table 1: ¹H NMR chemical shifts (δ) of STB and hydroxypropyl-β-cyclodextrin (HPβCD)

<table>
<thead>
<tr>
<th>Proton Type</th>
<th>δ (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STB</td>
<td></td>
</tr>
<tr>
<td>Ha</td>
<td>5.16</td>
</tr>
<tr>
<td>Hb</td>
<td>3.31</td>
</tr>
<tr>
<td>Hc</td>
<td>4.08</td>
</tr>
<tr>
<td>Hd</td>
<td>2.92, 3.84</td>
</tr>
<tr>
<td>He, Hf</td>
<td>6.92 - 8.07</td>
</tr>
<tr>
<td>Hg</td>
<td>10.14</td>
</tr>
<tr>
<td>Hh</td>
<td>2.15</td>
</tr>
<tr>
<td>Hi</td>
<td>9.36</td>
</tr>
</tbody>
</table>
Table 2: Maximum tolerated doses (MTD) of STB*RAMEβCD complex and As$_2$O$_3$ – daily doses proposed for the treatment of each group of mice.

<table>
<thead>
<tr>
<th></th>
<th>MTD*</th>
<th>Treatment - daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>STB/RAMEβCD i.p.</td>
<td>0.18 mmol/kg</td>
<td>0.12 mmol/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(65% MTD i.p.)</td>
</tr>
<tr>
<td>As$_2$O$_3$ i.p.</td>
<td>0.08 mmol/kg</td>
<td>0.052 mmol/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(65% MTD i.p.)</td>
</tr>
<tr>
<td>STB/RAMEβCD oral</td>
<td>&gt; 3 mmol/kg</td>
<td>1.2 mmol/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(10 fold i.p. dose)</td>
</tr>
<tr>
<td>As$_2$O$_3$ oral</td>
<td>0.4 mmol/kg</td>
<td>0.26 mmol/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(65% MTD oral)</td>
</tr>
</tbody>
</table>

* The maximum tolerated dose (MTD) was determined after 3 weeks of treatment in 5 mice. Criteria: no weight loss of ≥ 15% and no death.
Table 3: Amount of arsenic in organs of mice treated with STB\(^{*}\)HP\(\beta\)CD during 28 days.

<table>
<thead>
<tr>
<th>Amount of arsenic (nmol/g of tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>i.p</td>
</tr>
<tr>
<td>(n = 2)</td>
</tr>
<tr>
<td>Per os</td>
</tr>
<tr>
<td>(n = 3)</td>
</tr>
</tbody>
</table>

Mice alive at the end of the study (STB/HP\(\beta\)CD, day 28) are indicated in parentheses.

![Chemical Structure](image)

Arstholn
Chemical Formula: C\(_{11}\)H\(_{14}\)AsNO\(_3\)S\(_2\)
Molecular Weight: 347,29
1) Preparation and characterization of an arabinol/hydroxypropyl-β-cyclodextrin complex

2) Implantation of tumors (U87 glioma cell line)

3) Administration of the arabinol/hydroxypropyl-β-cyclodextrin complex or As2O3

4) Survival study